Universidad Peruana Cayetano Heredia

Novel antibodies directed against the human erythropoietin receptor: Creating a basis for clinical implementation

Mostrar el registro sencillo del ítem

dc.contributor.author Maxwell, P.
dc.contributor.author Melendez-Rodríguez, F.
dc.contributor.author Matchett, K.B.
dc.contributor.author Aragones, J.
dc.contributor.author Ben-Califa, N.
dc.contributor.author Jaekel, H.
dc.contributor.author Hengst, L.
dc.contributor.author Lindner, H.
dc.contributor.author Bernardini, A.
dc.contributor.author Brockmeier, U.
dc.contributor.author Fandrey, J.
dc.contributor.author Grunert, F.
dc.contributor.author Oster, H.S.
dc.contributor.author Mittelman, M.
dc.contributor.author El-Tanani, M.
dc.contributor.author Thiersch, M.
dc.contributor.author Schneider Gasser, E.M.
dc.contributor.author Gassmann, M.
dc.contributor.author Dangoor, D.
dc.contributor.author Cuthbert, R.J.
dc.contributor.author Irvine, A.
dc.contributor.author Jordan, A.
dc.contributor.author Lappin, T.
dc.contributor.author Thompson, J.
dc.contributor.author Neumann, D.
dc.date.accessioned 2019-02-22T14:54:59Z
dc.date.available 2019-02-22T14:54:59Z
dc.date.issued 2014
dc.identifier.uri https://hdl.handle.net/20.500.12866/5685
dc.description.abstract Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment. en_US
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartofseries British Journal of Haematology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Animals en_US
dc.subject anemia en_US
dc.subject Risk Assessment en_US
dc.subject Risk assessment en_US
dc.subject human en_US
dc.subject Amino Acid Sequence en_US
dc.subject Article en_US
dc.subject immunoreactivity en_US
dc.subject risk assessment en_US
dc.subject Mice en_US
dc.subject immunology en_US
dc.subject immunohistochemistry en_US
dc.subject erythropoietin receptor en_US
dc.subject genetics en_US
dc.subject metabolism en_US
dc.subject animal tissue en_US
dc.subject nonhuman en_US
dc.subject rat en_US
dc.subject animal en_US
dc.subject mouse en_US
dc.subject Rats en_US
dc.subject Fluorescent Antibody Technique en_US
dc.subject Molecular Sequence Data en_US
dc.subject Flow Cytometry en_US
dc.subject procedures en_US
dc.subject animal cell en_US
dc.subject signal transduction en_US
dc.subject human tissue en_US
dc.subject Western blotting en_US
dc.subject cancer patient en_US
dc.subject recombinant erythropoietin en_US
dc.subject immune response en_US
dc.subject protein domain en_US
dc.subject biosynthesis en_US
dc.subject bone marrow biopsy en_US
dc.subject molecular genetics en_US
dc.subject messenger RNA en_US
dc.subject human cell en_US
dc.subject flow cytometry en_US
dc.subject monoclonal antibody en_US
dc.subject mass spectrometry en_US
dc.subject gene silencing en_US
dc.subject pleiotropy en_US
dc.subject amino acid sequence en_US
dc.subject Receptors, Erythropoietin en_US
dc.subject Antibodies, Monoclonal en_US
dc.subject fluorescent antibody technique en_US
dc.subject immunofluorescence en_US
dc.subject cancer growth en_US
dc.subject high performance liquid chromatography en_US
dc.subject Janus kinase 2 en_US
dc.subject nomenclature en_US
dc.subject Terminology as Topic en_US
dc.subject synthesis en_US
dc.subject cancer cell line en_US
dc.subject drug megadose en_US
dc.subject Erythropoietin receptor en_US
dc.subject Antibody en_US
dc.subject Cancer anaemia en_US
dc.subject cancer immunization en_US
dc.subject Chemistry Techniques, Synthetic en_US
dc.subject fluorescence activated cell sorting en_US
dc.subject Gene Silencing en_US
dc.subject genetic immunization en_US
dc.subject glycophorin C en_US
dc.subject immunoprecipitation en_US
dc.subject Immunoprecipitation en_US
dc.subject Neoplasm Proteins en_US
dc.subject receptor binding en_US
dc.subject Recombinant erythropoietin en_US
dc.subject STAT5 protein en_US
dc.subject tumor cell culture en_US
dc.subject Tumor Cells, Cultured en_US
dc.subject tumor growth en_US
dc.subject tumor protein en_US
dc.title Novel antibodies directed against the human erythropoietin receptor: Creating a basis for clinical implementation en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1111/bjh.13133
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.06
dc.relation.issn 1365-2141


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas